Search Results - "Rietschel, Petra" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

by Gogishvili, Miranda, Melkadze, Tamar, Makharadze, Tamta, Giorgadze, Davit, Dvorkin, Mikhail, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Gessner, Christian, Moreno-Jaime, Brizio, Passalacqua, Rodolfo, Li, Siyu, McGuire, Kristina, Kaul, Manika, Paccaly, Anne, Quek, Ruben G. W., Gao, Bo, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra
Published in Nature medicine (01.11.2022)

Get full text

Journal Article

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

by Li, Ying, Brendel, Matthew, Wu, Ning, Ge, Wenzhen, Zhang, Hao, Rietschel, Petra, Quek, Ruben G. W., Pouliot, Jean-Francois, Wang, Fei, Harnett, James
Published in Scientific reports (21.10.2022)

Get full text

Journal Article

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

by Kitano, Shigehisa, Shimizu, Toshio, Koyama, Takafumi, Ebata, Takahiro, Iwasa, Satoru, Kondo, Shunsuke, Shimomura, Akihiko, Fujiwara, Yutaka, Yamamoto, Noboru, Paccaly, Anne, Li, Siyu, Rietschel, Petra, Sims, Tasha
Published in Cancer chemotherapy and pharmacology (01.01.2021)

Get full text

Journal Article

Variates of Survival in Metastatic Uveal Melanoma

Variates of Survival in Metastatic Uveal Melanoma

by RIETSCHEL, Petra, PANAGEAS, Katherine S, HANLON, Christine, PATEL, Ami, ABRAMSON, David H, CHAPMAN, Paul B
Published in Journal of clinical oncology (01.11.2005)

Get full text

Journal Article

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50

by Freemantle, Nick, Xu, Yingxin, Wilson, Florence R., Guyot, Patricia, Chen, Chieh-I, Keeping, Sam, Konidaris, Gerasimos, Chan, Keith, Kuznik, Andreas, Atsou, Kokuvi, Glowienka, Emily, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra
Published in Therapeutic advances in medical oncology (2022)

Get full text

Journal Article

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

by Feliciano, Josephine Louella, McLoone, Dylan, Xu, Yingxin, Quek, Ruben G W, Kuznik, Andreas, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra, Guyot, Patricia, Konidaris, Gerasimos, Chan, Keith, Keeping, Sam, Wilson, Florence R, Freemantle, Nick
Published in Frontiers in oncology (04.04.2023)

Get full text

Journal Article

600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

by Kilickap, Saadettin, Sezer, Ahmet, Gümü, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, He, Xuanyao, Gullo, Giuseppe, Rietschel, Petra, Quek, Ruben GW
Published in Journal for immunotherapy of cancer (01.11.2023)

Get full text

Journal Article

597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

by Deme, Dániel, Öven, Bala, Göker, Erdem, Lang, Istvan, Brück, Patrick, Wenger, Michael, Munshi, Neru, Schell, Thomas, Ünsal-Kaçmaz, Kezi, Markman, Janet, Rietschel, Petra, Yang, Huyuan, Tuereci, Oezlem, Sahin, Ugur, Atmaca, Akin, Forde, Patrick
Published in Journal for immunotherapy of cancer (01.11.2023)

Get full text

Journal Article

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

by Hadigan, Colleen, Meigs, James B., Corcoran, Colleen, Rietschel, Petra, Piecuch, Sarah, Basgoz, Nesli, Davis, Benjamin, Sax, Paul, Stanley, Takara, Wilson, Peter W. F., D'Agostino, Ralph B., Grinspoon, Steven
Published in Clinical infectious diseases (01.01.2001)

Get full text

Journal Article

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

by Ricciuti, Biagio, Elkrief, Arielle, Lin, Jessica, Zhang, Jianjun, Alessi, Joao V., Lamberti, Giuseppe, Gandhi, Malini, Di Federico, Alessandro, Pecci, Federica, Wang, Xinan, Makarem, Maisam, Murilo Hidalgo Filho, Cassio, Gorria, Teresa, Saini, Arushi, Pabon, Cindy, Lindsay, James, Pfaff, Kathleen L., Welsh, Emma L., Nishino, Mizuki, Sholl, Lynette M., Rodig, Scott, Kilickap, Saadettin, Rietschel, Petra, McIntyre, Debra AG, Pouliot, Jean-Francois, Altan, Mehmet, Gainor, Justin F., Heymach, John V., Schoenfeld, Adam J., Awad, Mark M.
Published in JTO clinical and research reports (01.09.2024)

Get full text

Journal Article

Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma

Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma

by RIETSCHEL, Petra, WOLCHOK, Jedd D, KROWN, Susan, GERST, Scott, JUNGBLUTH, Achim A, BUSAM, Klaus, SMITH, Katherine, ORLOW, Irene, PANAGEAS, Katherine, CHAPMAN, Paul B
Published in Journal of clinical oncology (10.05.2008)

Get full text

Journal Article

Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy

Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy

by Rietschel, Petra, Corcoran, Colleen, Stanley, Takara, Basgoz, Nesli, Klibanski, Anne, Grinspoon, Steven
Published in Clinical infectious diseases (01.11.2000)

Get full text

Journal Article

PD-1 ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER

PD-1 ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER

by RIETSCHEL PETRA, LOWY ISRAEL
Year of Publication 25.01.2024

Get full text

Patent

PD-1 저해제의 투여에 의한 폐암 치료 방법

PD-1 저해제의 투여에 의한 폐암 치료 방법

by RIETSCHEL PETRA, LOWY ISRAEL
Year of Publication 22.11.2023

Get full text

Patent

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

by Sezer, Ahmet, Kilickap, Saadettin, Gümüş, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M, Cicin, Irfan, Bentsion, Dmitry, Gladkov, Oleg, Clingan, Philip, Sriuranpong, Virote, Rizvi, Naiyer, Gao, Bo, Li, Siyu, Lee, Sue, McGuire, Kristina, Chen, Chieh-I, Makharadze, Tamta, Paydas, Semra, Nechaeva, Marina, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Gullo, Giuseppe, Lowy, Israel, Rietschel, Petra
Published in The Lancet (British edition) (13.02.2021)

Get full text

Journal Article

A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC)

A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC)

by Rowlands, Tracey, Boyapati, Anita, Li, Siyu, Daly, Christopher, Seebach, Frank A., Lowy, Israel, Rietschel, Petra
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

폐암의 치료를 위한 항-PD-1 항체

폐암의 치료를 위한 항-PD-1 항체

by RIETSCHEL PETRA, LOWY ISRAEL
Year of Publication 24.10.2019

Get full text

Patent

Response to Letter to the Editor

Response to Letter to the Editor

by Makharadze, Tamta, Gogishvili, Miranda, Baramidze, Ana, Li, Siyu, Li, Yuntong, Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra
Published in Journal of thoracic oncology (01.07.2023)

Get full text

Journal Article

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

by Makharadze, Tamta, Gogishvili, Miranda, Melkadze, Tamar, Baramidze, Ana, Giorgadze, Davit, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Li, Siyu, Li, Yuntong, Kaul, Manika, Quek, Ruben G.W., Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra
Published in Journal of thoracic oncology (01.06.2023)

Get full text

Journal Article

A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC

A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC

by Drilon, Alexander E., Awad, Mark M., Gadgeel, Shirish M., Villaruz, Liza C, Sabari, Joshua K., Perez, Javier, Daly, Christopher, Patel, Shraddha, Li, Siyu, Seebach, Frank A., Lowy, Israel, Magnan, Heather D., Rietschel, Petra
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article